{"filings":[{"id":187265,"accession_number":"0001826466-24-000131","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nika Pharmaceuticals dismisses accountant OLAYINKA OYEBOLA & CO, appoints Boladale Lawal & Co","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Terminated OLAYINKA OYEBOLA & CO on Oct 2, 2024 after a discovery prompting reconsideration.","No services were performed by the prior accountant before termination.","Engaged Boladale Lawal & Co as independent auditor on Oct 5, 2024 to audit financial statements.","Exhibit 23.1 includes dismissal consent from the former accountant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187264,"accession_number":"0001826466-24-000128","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Nika Pharmaceuticals hires OLAYINKA OYEBOLA & CO as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged OLAYINKA OYEBOLA & CO (Chartered Accountants) as independent auditor on September 23, 2024.","Firm will audit the company's financial statements going forward.","No mention of predecessor auditor or any accounting disagreements in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203776,"accession_number":"0001826466-24-000096","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["2.01","4.01","9.01"],"status":"ready","headline":"Nika cancels May 2024 acquisition of Nika Pharmaceuticals Ltd; auditor resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 18, 2024, board cancelled the acquisition of Nika Pharmaceuticals, Ltd. effective May 9, 2024; subsidiary returned to Savov on Aug 23.","Nika no longer owns Nika Europe, Ltd. nor the factory/land assets acquired in May 2024.","Independent auditor Fruci & Associates II, PLLC resigned on Aug 21, 2024; company seeking new auditor.","Company states it will try to publish its 10-Q as early as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220348,"accession_number":"0001826466-24-000056","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Nika Pharmaceuticals acquires subsidiary and factory building valued at $2.05M; signs $958K supply agreement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Nika Pharmaceuticals, Ltd. from CEO Dimitar Savov for nominal 5,000 BGN (~$2,800).","Acquisition includes beneficial ownership of a production building and land in Sofia valued at $2,045,209.","Nika Europe, Ltd. signed a GMP vial production line supply agreement with Shanghai Marya for $957,670; down payment of $191,534 paid by CEO personally.","Equipment delivery and installation expected by end of Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220347,"accession_number":"0001826466-24-000050","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Nika Pharma acquires 40% of Nika Europe, now owns 80%; buys 4 technologies for $24,683","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger with Nika BioTechnology gave Nika Pharma an additional 40% stake in Nika Europe Ltd, bringing total to 80%.","Nika Europe Ltd acquired three generic drug technologies and one dietary supplement technology from AIPFPCB.","Purchase price was 45,000 BGN (~$24,683), paid by officer Dimitar Savov, who is also general manager of Nika Europe.","Acquired drug technologies: Menthyl Valerate 0.06g, Metamizole Sodium 500mg, Vinpocetine 10mg; supplement: Tribulus Terrestris extract 250mg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240006,"accession_number":"0001826466-24-000020","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nika Pharmaceuticals completes merger with Nika BioTechnology; increases preferred authorized shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger effective March 1, 2024; Nika BioTech shareholders receive 1 NKPH share per NIKA share.","Controlling shareholder Dimitar Slavchev Savov owns ~69% of merged entity's common and 100% of Preferred A.","Articles amended to increase authorized Preferred A shares from 10M to 15M, filed March 4, 2024.","Both companies had same board and officers; management unchanged post-merger.","Shareholders approved the merger on February 12, 2024, and the transaction closed as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240005,"accession_number":"0001826466-24-000005","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nika Pharmaceuticals dismisses auditor BF Borgers, appoints Fruci & Associates","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Dismissed independent accountant B F Borgers CPA PC effective February 14, 2024.","Engaged Fruci & Associates II, PLLC as new independent auditor on February 14, 2024.","Board states change in best interests; no disagreements or reportable events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274861,"accession_number":"0001826466-23-000033","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","3.03","5.01","5.06"],"status":"ready","headline":"Nika Pharmaceuticals provides Form 10 info, discloses ownership and auditor change as former shell","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Change of control completed Apr 1, 2022: Dimitar Savov acquired 87% of common stock for $140,000.","As of Aug 31, 2023, Savov holds 38.04% common stock and 100% preferred stock, controlling 100% voting power.","Company ceased to be a shell as of Apr 11, 2022; business focus on TNG production and dietary supplements.","Auditor changed: dismissed Pinnacle Accountancy Group on Aug 18, 2022; engaged BF Borgers CPA PC on Oct 24, 2022.","Common stock not traded on any exchange; approximately 64 holders of record as of Sept 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331447,"accession_number":"0001826466-22-000149","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Appoints Dr. Darena Stoykova Zlateva as Chief Scientific Officer effective Nov 12, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Zlateva appointed CSO of Nika Pharmaceuticals effective Nov 12, 2022.","She holds a PhD in Immunology and a medical degree; prior roles at Sofia Medical Academy and European Medical Association.","Employment contract signed with Nika Europe Ltd., in which Nika owns a 40% stake.","CSO will manage research projects, represent company at scientific forums, and formulate long-term research strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331446,"accession_number":"0001826466-22-000112","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Nika Pharmaceuticals dismisses Pinnacle Accountancy Group, engages BF Borgers CPA as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Pinnacle Accountancy Group of Utah effective August 18, 2022.","Engaged BF Borgers CPA, PC as independent auditor on October 24, 2022.","Board deemed change in best interests; no reported disagreements with former accountant.","Former accountant authorized to respond fully to successor's inquiries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348976,"accession_number":"0001826466-22-000105","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2022-08-22T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Centennial Growth Equities changes name to Nika Pharmaceuticals, authorizes 2.7B shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved name change from Centennial Growth Equities to Nika Pharmaceuticals.","Authorized common stock increased from 90M to 2.7B shares at $0.001 par value.","Subsequent amendment reduced par value to $0.0001 per share for common and preferred.","Bylaws amended to permit electronic notice and online shareholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365783,"accession_number":"0001826466-22-000034","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["2.01","3.03","5.06"],"status":"ready","headline":"Centennial Growth Equities acquires exclusive rights to TNG and supplements, exits shell status","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 15-year exclusive rights to manufacture and distribute Thymus Nuclear Glycoprotein (TNG) from VITAL FE.","Also acquired 15-year rights to dietary supplements Palmcarotilen and Fiziolong from MICAR 11.","Consideration: 8M preferred shares (to Dimitar Savov) for TNG rights; 2M preferred shares for supplement rights.","Preferred shares granted 1,000 votes each, giving Savov ~10B votes; company no longer a shell company.","Dimitar Savov is CEO/Director and is the owner of both VITAL (70%) and MICAR (100%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365782,"accession_number":"0001826466-22-000028","cik":1145604,"company_name":"NIKA PHARMACEUTICALS, INC","ticker":"NIKA","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Centennial Growth Equities changes control; Savov buys 87% stake, becomes CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dimitar Slavchev Savov purchased 11,489,000 shares (87%) from Phil E. Ray and other shareholders, triggering change of control on April 1, 2022.","Phil E. Ray resigned as Director, President, and CEO; A. Terry Ray resigned as Director and Secretary; both effective March 31, 2022, with no disagreements.","Savov and Clifford Redekop appointed Directors March 31; Savov named President, CEO, CFO; Redekop named Secretary effective April 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":211806938.39999998,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}